Expression of DMBT1 in Colorectal Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

145 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-30

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease.

Preliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management

NCT01371942

Colorectal Cancer

UNKNOWN

Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer

NCT01673607

Resectable Hepatic Metastases of Colorectal Cancer

UNKNOWN PHASE2

Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC)

NCT06930586

Cancer Brain Injury

RECRUITING

Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer

NCT02872779

Circulating Markers Metastatic Colorectal Cancer

COMPLETED NA

Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults

NCT02304978

Colorectal Cancer

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DMBT1 Protein, Human Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with colorectal cancer

Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.

Detection of the expression of DMTB1 by immunohistochemistry

Intervention Type OTHER

Patients with adenomatous polyps

Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.

Detection of the expression of DMTB1 by immunohistochemistry

Intervention Type OTHER

Control patients

Fresh tissue samples from individuals without colorectal carcinoma will be used as control.

Detection of the expression of DMTB1 by immunohistochemistry

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Detection of the expression of DMTB1 by immunohistochemistry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* for colon cancer: patients surgically treated for colorectal cancer at the Group of hospitals of the Catholic Institute of Lille.
* for adenomatous polyps : patients treated for adenomatous polyps at the Group of hospitals of the Catholic Institute of Lille.
* for controls: patients surgically treated for diverticular disease at the Group of hospitals of the Catholic Institute of Lille.